Demonstration of the Effect of Estrogen and Progesterone Receptors on Survival in Breast Cancer without Cytostatic and Hormonal Treatment in a Small Set of Patients
Authors:
J. Hochmann
Authors place of work:
Katedra biologických a lékařských věd FaF UK, Hradec Králové
Published in the journal:
Klin Onkol 2010; 23(1): 25-33
Category:
Původní práce
Summary
Background:
With respect to diagnostic and therapeutic progress, it may occur that the statistical sets of patients evaluated and treated with uniform methods are small. As a consequence, it is meaningful to check a greater number of statistical approaches. It is suitable to verify whether, for instance, the differences between the results (+) and (++) for estrogen and progesterone receptors (ER and PR) in breast cancer have an effect on the length of survival. This question could be answered with the use of several Kaplan‑ Meier survival curves. However, it is also profitable to judge the simple graph of survival in dependence on receptor concentration. Nevertheless, traditional regression brings too great an error to this method of assessment. Therefore, the use of orthogonal regression is much more precise. Since it can be assumed that no non‑revealable micro‑metastases were present at the time of operation in some patients with N0, it is possible to achieve healing ad integrum of them using only simple surgery. Consequently, we concluded that it was necessary to exclude from the evaluation the group of patients in N0 surviving 10 years (in the search for evidence of the post‑operative impact of age‑based reduction of blood estrogen on survival). Design and Subjects: We verified these considerations when monitoring the ER and PR influence on overall survival. We performed this analysis in an approximately 2‑year sample of 74 female patients who received the described treatment in Pardubice hospital. At the time of operation, 56 were postmenopausal and 21 of these postmenopausal patients were in stage N1. Methods and Results: ER and PR in breast tumours were examined in the cytosol of operational biopsies. Adjuvant radiological treatment was used in addition to the surgical treatment of primary tumours and their original and post‑operative metastases. In the case of premenopausal patients with ER, (+) therapeutic sterilization was performed. The finding of higher ER in postmenopausal surviving patients (in comparison to dead ones) was below the boundary of statistical significance. Also, longer survival in cases of higher ER concentrations in the group of dead N1 patients was below the boundary of statistical significance in the use of traditional regression. Therefore, we put together evidence from the group of surviving patients with evidence from the group of dead patients. In the case of N1 patients surviving 10 years, we rounded their survival period to 15 years for inclusion in the graph of survival dependence on ER. In the case of the combined (premenopausal with postmenopausal) group, statistical reliability appeared for longer survival of higher ER already in traditional regression. However, for the postmenopausal alone, the difference was statistically insignificant. Nevertheless, if we used orthogonal regression (similar to Deming regression) instead of traditional regression, then the reliability of the dependence of the length of survival on ER increased (in the last cited graph) to such a degree that it was statistically highly significant (at the level of 0.001) even in case of just postmenopausal patients. The same level of statistical reliability was achieved in the Kaplan‑ Meier analysis. Also in the case of PR – the higher concentrations of this receptor in survivors compared to dead patients were not statistically significant. But (in contrast to ER) in the case of PR, we observed a statistically significant increase in survival time depending on the receptor concentration within the group of only the dead patients – hence without putting them together with the surviving patients).
Conclusions:
The graph of the Kaplan‑ Meier analysis is more frequently used when solving these problems but the graph of simple dependence of survival on receptor concentration should not be neglected either because, for example, it better shows the difference in survival between ER(+) and (++). Nevertheless, it is necessary to use orthogonal regression in it. The greater suitability of PR and ER for short‑term and long‑term prognosis, respectively, which we identified in our statistical set, is in concordance with the literature.
Key words:
estrogen receptors – progesterone receptors – breast cancer – stage – TNM – survival – orthogonal regression – Kaplan‑ Meier analysis
Zdroje
1. Castagnetta LAM, Traina A, Liquori M et al. Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting brest cancer patients for therapy. Anal Quantit Cytol Histol 1999; 21(1): 59– 62.
2. Coradini D, Oriana S, Biganzoli E et al. Relationship between steroid receptors (as continous variables) and response to adjuvant treatments in postmenopausal women with node positive breast cancer. Int J Biol Markers 1999; 14(2): 60 67.
3. Costa SD, Lange S, Klinga K et al. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer – results of the analysis of 670 patients with 11 years of follow‑up. Eur J Cancer 2002; 38(10): 1329– 1334.
4. Dvořáková E. Hormonální receptory v nádorech prsu. Diplomová práce, školitel Hochmann J., Katedra biologických a lékařských věd. Hradec Králové: Farmaceutická fakulta Univerzity Karlovy 2007.
5. Hochmann J. The effect of age on the breast cancer estrogen receptor level. Klin Onkol 1999; 12(1): 22– 29.
6. Hochmann J. Diagnostical exploitation of the ratio of progesterone to estrogen receptors in breast. Klin Onkol 1999; 12(5): 174– 178.
7. Hochmann J. Ratio of concentrations of estrogen receptors to progesterone receptors (ER/ PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR). Neoplasma 2007; 54(4): 290– 296.
8. Hupperets PS, Volovics L, Schouten LJ et al. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 1997; 20(6): 546 51.
9. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invazive ductal breast carcinomas. Histopathology 1993; 23(3): 239– 248.
10. Martin JD, Hähnel R, McCartney AJ et al. The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecologic Oncol 1986; 23(3): 329– 335.
11. Pertschuk LP, Masood S, Simone J et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol oncol 1996; 63(1): 28– 33.
12. Petružalka L, Konopásek B, Tesařová P. Hormonální léčba – nové perspektivy a nové možnosti léčby postmenopauzálních žen s hormonálně dependentním karcinomem prsu. Lék Listy 2007; 56(9): 23– 25.
13. Pujol P, Daures JP, Thezenas S et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998; 83(4): 698 705.
14. Raabe NK, Hagen S, Haug E et al. Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma. Int J Oncol 1998; 12(5): 1091–1096.
15. Sauerbrei W, Hubner K, Schmoor C et al. Validation of existing and development of new prognostic clasification schemes in node negative breast cancer. Breast Cancer Res Treat 1997; 42: 149 163.
16. Ruder AM, Lubin F, Wax Y et al. Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences. Cancer 1989; 64(1): 196– 202. http:/ / www3.interscience.wiley.com/ journal/ 112685931/ abstract.
17. Thorpe SM, Christensen IJ, Rasmussen BB et al. Short recurence‑free survival associated with high estrogen receptor levels in the natural‑ history of postmenopausal primary breast cancer. Europ J Cancer 1993; 29A(7): 971– 977.
18. Younes M, Lane M, Miller CC et al. Stratified multivariate analysis of prognostic markers in breast cancer: a preliminary report. Anticancer Res 1997; 17 (2B): 1383 1390.
Štítky
Detská onkológia Chirurgia všeobecná OnkológiaČlánok vyšiel v časopise
Klinická onkologie
2010 Číslo 1
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
- Kombinace metamizol/paracetamol v léčbě pooperační bolesti u zákroků v rámci jednodenní chirurgie
- Tramadol a paracetamol v tlumení poextrakční bolesti
Najčítanejšie v tomto čísle
- Velmi malé karcinomy prsu, HER2-pozitivní a léčba trastuzumabem v adjuvanci
- NK buňky, chemokiny a chemokinové receptory
- Průkaz vlivu estrogenových a progesteronových receptorů na přežití u karcinomu prsu bez cytostatické a hormonální léčby v malém souboru pacientek
- Dlouhodobá odpověď jaterních metastáz karcinomu prsu na léčbu kapecitabinem – kazuistické sdělení